Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity persistence in adolescents/young adults up to 7.5 years post-primary vaccination with 4CMenB, and response to a booster dose compared with vaccine-naïve controls.
This open-label, multicentre study enrolled 15-24 year-old-previously vaccinated participants from Canada, Australia and Chile. For all antigens bar one (the Neisserial Heparin Binding Antigen, NHBA), a higher proportion of primed participants had clinically relevant antibody responses, at 4 and 7.5 years post-vaccination, compared with vaccine-naïve participants. A more robust immune response after booster compared to a first dose in vaccine-naïve individuals, showed effective priming in an adolescent/young adult population. No safety or new reactogenicity issues were identified.
To read more, visit https://pubmed.ncbi.nlm.nih.gov/30691980/